OTCM
ASCLF
Market cap766mUSD
Oct 20, Last price
0.75
Name
Ascletis Pharma Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-1.33%
Rev. 5Y
-43.43%
Div Yld LY
—
Div Yld TTM
—
Revenues
2m
+58.07%
Net income
-360m
L+19.59%
CFO
-329m
L-3.62%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Key people
Judy Hejingdao Wu
Senior Vice President, Executive Director · since 2021
Handan He
Chief Scientific Officer · since 2019
Jinzi Jason Wu
Executive Chairman of the Board, Chief Executive Officer · since 2018
Yuemei Yan
Senior Vice President of Clinical Development and Operations, Sales Director · since 2021
Company Secretary · since 2022
Non-Executive Independent Director · since 2018
Lin Hua
Non-Executive Independent Director · since 2018
Yizhen Wei
Non-Executive Independent Director · since 2018
Legal address
C/O Walkers Corporate Limited
190 Elgin Avenue
Grand Cayman
George Town KY1-9008
KY
190 Elgin Avenue
Grand Cayman
George Town KY1-9008
KY
Headquarters
40th Floor, Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong 999077
HK
No. 248 Queen's Road East
Wanchai
Hong Kong 999077
HK
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||